203,853 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, HoldingsChannel reports. The firm bought 203,853 shares of the company’s stock, valued at approximately $3,908,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Ameriprise Financial Inc. grew its position in Viridian Therapeutics by 16.2% during the fourth quarter. Ameriprise Financial Inc. now owns 48,793 shares of the company’s stock worth $935,000 after buying an additional 6,806 shares in the last quarter. Foresite Capital Management VI LLC acquired a new stake in Viridian Therapeutics during the fourth quarter valued at approximately $38,000. Northern Trust Corp boosted its holdings in Viridian Therapeutics by 19.3% during the fourth quarter. Northern Trust Corp now owns 694,142 shares of the company’s stock valued at $13,307,000 after purchasing an additional 112,534 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Viridian Therapeutics by 101.0% during the fourth quarter. The Manufacturers Life Insurance Company now owns 49,720 shares of the company’s stock valued at $953,000 after purchasing an additional 24,988 shares in the last quarter. Finally, Tudor Investment Corp ET AL boosted its holdings in Viridian Therapeutics by 3.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company’s stock valued at $735,000 after purchasing an additional 1,106 shares in the last quarter.

Viridian Therapeutics Stock Down 3.4%

Shares of VRDN opened at $12.38 on Thursday. The company has a market capitalization of $1.01 billion, a P/E ratio of -2.87 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20. The business’s 50 day simple moving average is $13.53 and its 200-day simple moving average is $17.31.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics’s revenue was up .0% compared to the same quarter last year. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on VRDN. JMP Securities decreased their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Needham & Company LLC decreased their price objective on Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group decreased their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Finally, Royal Bank of Canada decreased their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.